The Cigna Group CI

Cigna Corporation es una empresa de servicios de salud que ofrece seguros médicos, dentales y productos y servicios relacionados. Los segmentos de la compañía incluyen Evernorth y Cigna Healthcare. El segmento de Evernorth incluye una variedad de servicios de salud coordinados y soluciones puntuales, así como los de socios en todo el sistema de atención médica, en soluciones de farmacia, soluciones de gestión de beneficios, soluciones de entrega de atención y gestión de la atención y soluciones de inteligencia. Cigna Healthcare consta de sus segmentos operativos de Salud Comercial de EE. UU., Gobierno de EE. UU. y Salud Internacional, que ofrecen una variedad de soluciones médicas y coordinadas a clientes y clientes para apoyar las necesidades de salud de toda la persona. Los productos y servicios comerciales de EE. UU. incluyen atención médica, farmacia, salud conductual, dental, visión, programas de defensa de la salud y otros productos y servicios para clientes asegurados y autoasegurados. Las soluciones de salud internacional incluyen cobertura de atención médica en sus mercados internacionales.

Con 4 acciones de CI (USD 1.084,07) habrías recibido USD 24,76 en dividendos en los últimos 12 meses.

• Zacks Investment Research 10 sept

  Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?

  CVS Health's Pharmacy & Consumer Wellness segment showed strong growth with operating income up 10.2% year-over-year to $1.48 billion in Q2 2026, supported by higher prescription volumes and improved margins. The company raised its 2026 operating income outlook for the segment by $220 million. CVS is expanding AI tools including Health100 and Claims Assist Manager to improve efficiency and customer service. However, reimbursement pressure, regulatory scrutiny, and insufficient Medicare Advantage payment updates remain key headwinds. With a discounted valuation (P/S of 0.29X vs. industry average 0.53X), Zacks recommends current holders maintain positions while prospective investors wait for a more favorable entry point.

  

• Zacks Investment Research 10 sept

  BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?

  BrightSpring Health Services (BTSG) reported strong Q2 2026 results with Specialty and Infusion revenue growing 30% and scripts rising 31%, driven by branded limited distribution drugs (LDDs) and expansion into rare and orphan therapies. The company added two new LDDs, bringing its portfolio to 155 programs with 12 launched in 2026. Pharmacy Solutions adjusted EBITDA increased 44% to $180 million. Peers Cigna and Humana also showed strength in specialty pharmacy segments, though with different growth drivers.

  

• Zacks Investment Research 27 ago

  Can Cigna's Smart Coverage Help Close Health-Cost Gaps?

  Cigna Healthcare is introducing Smart Coverage, a new benefit option that automatically links medical claims with supplemental benefits to provide eligible members up to $7,000 for covered health events. The program launches January 1, 2027, for mid-sized employers and addresses a significant affordability gap, with nearly 60% of Americans unprepared for health costs. The initiative is designed to increase enrollment in high-deductible plans and boost supplemental product participation.

  

• GlobeNewswire Inc. 27 jul

  Sale Proposal for The Dolphin Company to Grupo Xcaret Threatens 90% Monopoly and Violates Court Rulings

  The Dolphin Company's management has proposed selling its Mexican assets to Delphinus Blue Planet (Grupo Xcaret subsidiary) for $20 million, a deal that would violate Mexican Supreme Court rulings and create a 90% monopoly in dolphin habitat tourism. The proposal was filed in U.S. Bankruptcy Court despite an active judicial stay from Mexico's highest court prohibiting asset sales without authorization.

  

• The Motley Fool 21 jul

  Prediction: U.S. Value Stocks Will Outperform for 10 Years. Which ETFs Should You Buy?

  Vanguard research forecasts that U.S. value stocks and small-cap stocks will outperform growth stocks over the next 10 years. The article compares two Vanguard ETFs for value stock exposure: the Vanguard Small-Cap Value ETF (VBR), a passively managed fund with ultra-low fees, and the Vanguard U.S. Value Factor ETF (VFVA), an actively managed alternative with broader market-cap exposure. Both funds have recently outperformed the S&P 500 and Nasdaq-100.